We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

26 hedge funds and large institutions have $1.35M invested in Traws Pharma in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

7% more capital invested

Capital invested by funds: $1.27M → $1.35M (+$82.9K)

0.01% more ownership

Funds ownership: 0.34% → 0.35% (+0.01%)

4% less funds holding

Funds holding: 27 → 26 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MG
Marex Group
+$101K
2
Renaissance Technologies
Renaissance Technologies
New York
+$10.3K
3
UBS Group
UBS Group
Switzerland
+$5.16K
4
Millennium Management
Millennium Management
New York
+$2.62K
5
Bank of America
Bank of America
North Carolina
+$442

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$58K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$22.2K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$11.5K
4
TSS
Two Sigma Securities
New York
-$7.78K
5
Morgan Stanley
Morgan Stanley
New York
-$851

TRAW Hedge Fund Activity: Q4 2023 in Review

26 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2023, worth a combined $1.35M — up 6.5% from $1.27M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TRAW and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.

The largest buyer was Marex Group, opening a new position worth an estimated $101K. The largest seller was Two Sigma Investments, cutting an estimated $58K.

  • 26 institutional investors held Traws Pharma (TRAW) as of Q4 2023, down from 27 in Q3 2023.
  • Funds reported $1.35M of Traws Pharma stock for Q4 2023, up 6.5% quarter-over-quarter.
  • 2 funds opened new Traws Pharma positions in Q4 2023 and 3 closed out, a net change of -1 holder.
  • The largest Traws Pharma buyer in Q4 2023 was Marex Group, an estimated $101K added.
  • The largest Traws Pharma seller in Q4 2023 was Two Sigma Investments, an estimated $58K sold.

Based on aggregated 13F filings for Q4 2023.